Vertex Pharmaceuticals Incorporated (VRTX)

(NasdaqGS: VRTX)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Vertex Pharmaceuticals Incorporated To Contact the Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) (NasdaqGS: VRTX).

The investigation focuses on whether the Company and its executives violated federal securities laws by misrepresenting the results of its Phase 2 study of its experimental drugs VX-909 and Kalydeco in statements made on May 7, 2012 and May 29, 2012. On June 27, 2012 the Company admitted that those prior statements regarding the Phase 2 study were inaccurate and Vertex's stock price declined significantly on the news.

Take Action

If you purchased Vertex stock or options between May 7, 2012 and June 27, 2012 and would like to discuss your legal rights, contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to or  Faruqi & Faruqi, LLP also encourages anyone with information regarding Vertex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.


Request Information

  Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you. If you want to be a Lead Plaintiff or join
this action now, please click HERE.
Case:Vertex Pharmaceuticals Incorporated (VRTX)

Case Details

Contact Counsel

Richard W. Gonnello
Francis P. McConville
Faruqi & Faruqi, LLP
369 Lexington Avenue 10th Floor
New York, NY 10017
Tel: (212) 983-9330

Send Information

If you have information regarding this case that you would
like to make available, please click here to contact us
about our investigation